C7R-EBVSTs

C7R-EBVSTs is an investigational autologous cell therapy consisting of Epstein-Barr virus-specific T-cells (EBVSTs) genetically modified to express a chimeric antigen receptor (CAR) targeting CD70 and a constitutively active interleukin-7 receptor (C7R). The CAR component is derived from the extracellular domain of human CD27, the natural binding partner for CD70, which allows the engineered T-cells to recognize and eliminate CD70-expressing malignant cells. The inclusion of the C7R modification provides continuous IL-7 cytokine signaling, which is designed to enhance the persistence, expansion, and anti-tumor activity of the T-cells within the immunosuppressive tumor microenvironment. Developed by Baylor College of Medicine, this therapy is being evaluated in Phase 1 clinical trials (such as the CASEY and SEVENTY studies) for patients with relapsed or refractory hematologic malignancies, including acute myeloid leukemia (AML), B-cell leukemia, and T-cell leukemia.

Other names

Treatment Arm A-Baylor College of Medicine-acute myeloid leukemia-B-cell leukemia-T-cell leukemiaCD70-targeted CAR T-cellsCD-70-targeted CAR T-cellsCD 70-targeted CAR T-cellsCD70.CARCD-70.CARCD 70.CARTreatment Arm ACD70 CAR T-cell TherapyCD-70 CAR T-cell TherapyCD 70 CAR T-cell TherapyCD27-CD3z-C7R CAR T-cellsCD-27-CD3z-C7R CAR T-cellsCD 27-CD3z-C7R CAR T-cells